|
1
|
Herrmann J, Lerman LO and Lerman A:
Ubiquitin and ubiquitin-like proteins in protein regulation. Circ
Res. 100:1276–1291. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Flotho A and Melchior F: Sumoylation: A
regulatory protein modification in health and disease. Annu Rev
Biochem. 82:357–385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bohren KM, Nadkarni V, Song JH, Gabbay KH
and Owerbach D: A M55V polymorphism in a novel SUMO gene (SUMO-4)
differentially activates heat shock transcription factors and is
associated with susceptibility to type I diabetes mellitus. J Biol
Chem. 279:27233–27238. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Geiss-Friedlander R and Melchior F:
Concepts in sumoylation: A decade on. Nat Rev Mol Cell Biol.
8:947–956. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tatham MH, Jaffray E, Vaughan OA, Desterro
JM, botting CH, Naismith JH and Hay RT: Polymeric chains of SUMO-2
and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and
Ubc9. J Biol Chem. 276:35368–35374. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang W and Paschen W: SUMO proteomics to
decipher the SUMO-modified proteome regulated by various diseases.
Proteomics. 15:1181–1191. 2015. View Article : Google Scholar :
|
|
7
|
Hannich JT, Lewis A, Kroetz MB, Li SJ,
Heide H, Emili A and Hochstrasser M: Defining the SUMO-modified
proteome by multiple approaches in Saccharomyces cerevisiae. J Biol
Chem. 280:4102–4110. 2005. View Article : Google Scholar
|
|
8
|
Hecker CM, Rabiller M, Haglund K, Bayer P
and Dikic I: Specification of SUMO1- and SUMO2-interacting motifs.
J Biol Chem. 281:16117–16127. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Song J, Durrin LK, Wilkinson TA, Krontiris
TG and Chen Y: Identification of a SUMO-binding motif that
recognizes SUMO-modified proteins. Proc Natl Acad Sci USA.
101:14373–14378. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kumar A and Zhang KY: Advances in the
development of SUMO specific protease (SENP) inhibitors. Comput
Struct Biotechnol J. 13:204–211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hickey CM, Wilson NR and Hochstrasser M:
Function and regulation of SUMO proteases. Nat Rev Mol Cell Biol.
13:755–766. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bettermann K, Benesch M, Weis S and
Haybaeck J: SUMOylation in carcinogenesis. Cancer Lett.
316:113–125. 2012. View Article : Google Scholar
|
|
13
|
Olsen SK, Capili AD, Lu X, Tan DS and Lima
CD: Active site remodelling accompanies thioester bond formation in
the SUMO E1. Nature. 463:906–912. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kumar A, Ito A, Hirohama M, Yoshida M and
Zhang KY: Identification of sumoylation inhibitors targeting a
predicted pocket in Ubc9. J Chem Inf Model. 54:2784–2793. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kumar A, Ito A, Hirohama M, Yoshida M and
Zhang KY: Identification of sumoylation activating enzyme 1
inhibitors by structure-based virtual screening. J Chem Inf Model.
53:809–820. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mattoscio D and Chiocca S: SUMO pathway
components as possible cancer biomarkers. Future Oncol.
11:1599–1610. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schulz S, Chachami G, Kozaczkiewicz L,
Winter U, Stankovic-Valentin N, Haas P, Hofmann K, Urlaub H, Ovaa
H, Wittbrodt J, et al: Ubiquitin-specific protease-like 1 (USPL1)
is a SUMO isopeptidase with essential, non-catalytic functions.
EMbO Rep. 13:930–938. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shin EJ, Shin HM, Nam E, Kim WS, Kim JH,
Oh BH and Yun Y: DeSUMOylating isopeptidase: A second class of SUMO
protease. EMBO Rep. 13:339–346. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shirong L and Wei H: Sumoylation - a
muitffunctional post-translational protein modification. J Med Mol
Biol. 3:212–215. 2006.
|
|
20
|
Liu X, Xu Y, Pang Z, Guo F, Qin Q, Yin T,
Sang Y, Feng C, Li X, Jiang L, et al: Knockdown of SUMO-activating
enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances
chemotherapy sensitivity in small cell lung cancer. J Hematol
Oncol. 8:672015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen SF, Gong C, Luo M, Yao HR, Zeng YJ
and Su FX: Ubc9 expression predicts chemoresistance in breast
cancer. Chin J Cancer. 30:638–644. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rabellino A, Carter B, Konstantinidou G,
Wu SY, Rimessi A, byers LA, Heymach JV, Girard L, Chiang CM,
Teruya-Feldstein J, et al: The SUMO E3-ligase PIAS1 regulates the
tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer
Res. 72:2275–2284. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li T, Huang S, Dong M, Gui Y and Wu D:
Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate
cancer patients undergoing radical prostatectomy. Urol Oncol.
31:1539–1545. 2013. View Article : Google Scholar
|
|
24
|
Bossis G, Sarry JE, Kifagi C, Ristic M,
Saland E, Vergez F, Salem T, Boutzen H, Baik H, Brockly F, et al:
The ROS/SUMO axis contributes to the response of acute myeloid
leukemia cells to chemotherapeutic drugs. Cell Rep. 7:1815–1823.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dassouki Z, Sahin U, El Hajj H, Jollivet
F, Kfoury Y, Lallemand-Breitenbach V, Hermine O, de Thé H and
Bazarbachi A: ATL response to arsenic/interferon therapy is
triggered by SUMO/PML/RNF4-dependent Tax degradation. Blood.
125:474–482. 2015. View Article : Google Scholar
|
|
26
|
Chen Y, Horne D, Li YJ, Ma LY,
Perkins-Harki AL and Su Y: Multi-valent poly-ubl chain inhibitors
and methods of use. US Patent 0302815. Filed February 21, 2012;
issued August 5, 2014.
|
|
27
|
Zhao B, Villhauer EB, Bhuripanyo K,
Kiyokawa H, Schindelin H and Yin J: SUMO-mimicking peptides
inhibiting protein SUMOylation. Chembiochem. 15:2662–2666. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Butterworth KT, Coulter JA, Jain S, Forker
J, McMahon SJ, Schettino G, Prise KM, Currell FJ and Hirst DG:
Evaluation of cytotoxicity and radiation enhancement using 1.9 nm
gold particles: Potential application for cancer therapy.
Nanotechnology. 21:2951012010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li YJ, Perkins AL, Su Y, Ma Y, Colson L,
Horne DA and Chen Y: Gold nanoparticles as a platform for creating
a multivalent poly-SUMO chain inhibitor that also augments ionizing
radiation. Proc Natl Acad Sci USA. 109:4092–4097. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chithrani DB, Jelveh S, Jalali F, van
Prooijen M, Allen C, Bristow RG, Hill RP and Jaffray DA: Gold
nanoparticles as radiation sensitizers in cancer therapy. Radiat
Res. 173:719–728. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Langston SP, Olhava EJ and Vyskocil S:
Inhibitors of E1 activating enzymes. EP Patent 2402334 A1. Filed
February 2, 2006; issued Junuary 26, 2012.
|
|
32
|
Soucy TA, Smith PG, Milhollen MA, Berger
AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP,
Critchley S, et al: An inhibitor of NEDD8-activating enzyme as a
new approach to treat cancer. Nature. 458:732–736. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Diffey MO, England Db, Hu ZG, Ito M,
Langston SP, Mcintyre C, Mizutani H and Xu H: Heteroaryl compounds
useful as inhibitors of SUMO activating enzyme. WO Patent
2015002994 A2. Filed July 1, 2014; issued January 8, 2015.
|
|
34
|
Driscoll JJ, Pelluru D, Lefkimmiatis K,
Fulciniti M, Prabhala RH, Greipp PR, Barlogie B, Tai YT, Anderson
KC, Shaughnessy JD Jr, et al: The sumoylation pathway is
dysregulated in multiple myeloma and is associated with adverse
patient outcome. Blood. 115:2827–2834. 2010. View Article : Google Scholar :
|
|
35
|
Kessler JD, Kahle KT, Sun T, Meerbrey KL,
Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, et
al: A SUMOylation-dependent transcriptional subprogram is required
for Myc-driven tumorigenesis. Science. 335:348–353. 2012.
View Article : Google Scholar
|
|
36
|
Chen Y, Li YJ, Divlianska D, Bobkova E and
Roth G: Singleton inhibitors of SUMOylation enzymes and methods for
their use. US Patent 20130317101 A1. Filed May 9, 2013; issued
November 28, 2013.
|
|
37
|
Chen Y and Li YJ: Singleton inhibitors of
SUMOylation enzymes and methods for their use. WO Patent 064898 A1.
Filed May 9, 2013; issued January 19, 2016.
|
|
38
|
Maas M, Nelemans PJ, Valentini V, Crane
CH, Capirci C, Rödel C, Nash GM, Kuo LJ, Glynne-Jones R,
García-Aguilar J, et al: Adjuvant chemotherapy in rectal cancer:
Defining subgroups who may benefit after neoadjuvant chemoradiation
and resection: A pooled analysis of 3,313 patients. Int J Cancer.
137:212–220. 2015. View Article : Google Scholar
|
|
39
|
García-Aguilar J, Hernandez de Anda E,
Sirivongs P, Lee SH, Madoff RD and Rothenberger DA: A pathologic
complete response to preoperative chemoradiation is associated with
lower local recurrence and improved survival in rectal cancer
patients treated by mesorectal excision. Dis Colon Rectum.
46:298–304. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen Y and Li YJ: Bicyclic and tricyclic
inhibitors of SUMOylation enzymes and methods for their use. WO
Patent 064897 A2. Filed November 9, 2011; issued May 18, 2012.
|
|
41
|
Chen Y, Li YJ, Divlianska D, Bobkova E,
Roth G, Jun PU and Khan P: Bicyclic and tricyclic inhibitors of
SUMOylation enzymes and methods for their use. US Patent
20130245032 A1. Filed May 9, 2013; issued September 19, 2013.
|
|
42
|
Chen Y, Li YJ, Divlianska D, bobkova E,
Roth G, Jun PU and Khan P: Inhibitors of small ubiquitin-like
modifier enzymes with substituted pyrrolo(2,3-B)quinoxalines. US
Patent 9045483 B2. Filed May 9, 2013; issued June 2, 2015.
|
|
43
|
Lalonde JP, Lim R, Scaife R, Gallagher S
and Klinken SP: HLS-5 a control SUMOylation agent. EP Patent
2545935 A1. Filed October 6, 2006; issued January 16, 2013.
|
|
44
|
Klinken SP, Lalonde JP, Lim R, Scaife R
and Gallagher S: SUMOylation control agent and uses thereof. US
Patent 20130330738 A1. Filed Junuary 4, 2013; issued December 12,
2013.
|
|
45
|
Knuutila S, Aalto Y, Autio K, Björkqvist
AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S,
Larramendy ML, et al: DNA copy number losses in human neoplasms. Am
J Pathol. 155:683–694. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lalonde JP, Lim R, Ingley E, Tilbrook PA,
Thompson MJ, McCulloch R, Beaumont JG, Wicking C, Eyre HJ,
Sutherland GR, et al: HLS5, a novel RBCC (ring finger, B box,
coiled-coil) family member isolated from a hemopoietic lineage
switch, is a candidate tumor suppressor. J Biol Chem.
279:8181–8189. 2004. View Article : Google Scholar
|
|
47
|
Kimura F, Suzu S, Nakamura Y, Nakata Y,
Yamada M, Kuwada N, Matsumura T, Yamashita T, Ikeda T, Sato K, et
al: Cloning and characterization of a novel RING-B-box-coiled-coil
protein with apoptotic function. J Biol Chem. 278:25046–25054.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Alshareeda AT, Negm OH, Green AR, Nolan C,
Tighe P, Albarakati N, Sultana R, Madhusudan S, Ellis IO and Rakha
EA: SUMOylation proteins in breast cancer. Breast Cancer Res Treat.
144:519–530. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Coppola D, Parikh V, boulware D and Blanck
G: Substantially reduced expression of PIAS1 is associated with
colon cancer development. J Cancer Res Clin Oncol. 135:1287–1291.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen P, Zhao D, Sun Y, Huang L, Zhang S
and Yuan Y: Protein inhibitor of activated STAT-1 is downregulated
in gastric cancer tissue and involved in cell metastasis. Oncol
Rep. 28:2149–2155. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wei J, Costa C, Ding Y, Zou Z, Yu L,
Sanchez JJ, Qian X, Chen H, Gimenez-Capitan A, Meng F, et al: mRNA
expression of bRCA1, PIAS1, and PIAS4 and survival after
second-line docetaxel in advanced gastric cancer. J Natl Cancer
Inst. 103:1552–1556. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hoefer J, Schäfer G, Klocker H, Erb HH,
Mills IG, Hengst L, Puhr M and Culig Z: PIAS1 is increased in human
prostate cancer and enhances proliferation through inhibition of
p21. Am J Pathol. 180:2097–2107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chen Y, Li S, Li S, Li YJ, Su Y, Wong S
and Zaia J: Inhibitors of deSUMOylation enzymes and methods for
their use. WO Patent 2012064887 A1. Filed November 9, 2011; issued
May 18, 2012.
|
|
54
|
Chen Y: Methods of identifying SENP1
inhibitors. US Patent 20140302525 A1. Filed April 7, 2014; issued
October 9, 2014.
|
|
55
|
Madu IG, Namanja AT, Su Y, Wong S, Li YJ
and Chen Y: Identification and characterization of a new chemotype
of noncovalent SENP inhibitors. ACS Chem Biol. 8:1435–1441. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chen CH, Namanja AT and Chen Y:
Conformational flexibility and changes underlying activation of the
SUMO-specific protease SENP1 by remote substrate binding. Nat
Commun. 5:49682014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Madu IG, Li S, Li B, Li H, Chang T, Li YJ,
Vega R, Rossi J, Yee JK, Zaia J, et al: A Novel Class of HIV-1
Antiviral Agents Targeting HIV via a SUMOylation-Dependent
Mechanism. Sci Rep. 5:178082015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang LS, Sun HY, Wu ZZ, Xiao FJ, Wang H
and Yang YF: SENP1 protein inhibitors and uses thereof. CN Patent
104436196 A. Filed September 23, 2013; issued March 25, 2015.
|
|
59
|
Zhang J, Cheng JK, Lu SY, Cheng YY, Zhang
JM and Huang M: Senp1 small molecule inhibitors and their
applications. CN Patent 103961348 B. Filed February 5, 2013; issued
August 17, 2016.
|
|
60
|
Chen Y, Wen D, Huang Z, Huang M, Luo Y,
Liu B, Lu H, Wu Y, Peng Y and Zhang J:
2-(4-Chlorophenyl)-2-oxoethyl 4-benzamidobenzoate derivatives, a
novel class of SENP1 inhibitors: Virtual screening, synthesis and
biological evaluation. Bioorg Med Chem Lett. 22:6867–6870. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cheng J, Kang X, Zhang S and Yeh ET:
SUMO-specific protease 1 is essential for stabilization of
HIF1alpha during hypoxia. Cell. 131:584–595. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Bawa-Khalfe T, Cheng J, Lin SH, Ittmann MM
and Yeh ET: SENP1 induces prostatic intraepithelial neoplasia
through multiple mechanisms. J Biol Chem. 285:25859–25866. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yamaguchi T, Sharma P, Athanasiou M, Kumar
A, Yamada S and Kuehn MR: Mutation of SENP1/SuPr-2 reveals an
essential role for desumoylation in mouse development. Mol Cell
Biol. 25:5171–5182. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Cheng J, Bawa T, Lee P, Gong L and Yeh ET:
Role of desumoylation in the development of prostate cancer.
Neoplasia. 8:667–676. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhang J, Cheng JK, Huang M, Chen YY, Huang
ZM, Lu SY and Shi T: SENP2 small molecule inhibitor and
applications thereof. CN Patent 103877078 A. Filed December 20,
2012; issued June 25, 2014.
|
|
66
|
Dou QP and Zonder JA: Overview of
proteasome inhibitor-based anticancer therapies: Perspective on
bortezomib and second generation proteasome inhibitors versus
future generation inhibitors of ubiquitin-proteasome system. Curr
Cancer Drug Targets. 14:517–536. 2014. View Article : Google Scholar
|
|
67
|
Chen JW, Ink BS and Lewis AP: Cysteine
protease polypeptides GB2371801. 2002
|
|
68
|
Ink BS and Lewis AP: Cysteine protease
polypeptide GB2372504. 2002
|
|
69
|
Chen JW, Ink BS and Lewis AP: Cysteine
protease polypeptide GB2372994. 2002
|
|
70
|
Ink BS: Protease polypeptide GB2382078.
2003
|
|
71
|
Góra J and Latajka R: Involvement of
cysteine proteases in cancer. Curr Med Chem. 22:944–957. 2015.
View Article : Google Scholar
|
|
72
|
Wu HJ, Liu WD, Hong YD and Guo QP:
Identification of a breast cancer suppressor and methods for use
CN101923095. 2010
|
|
73
|
German RA and Sangita P: Modulation of
cellular protein function by artifical SUMO ligases. US Patent
20120246757 A1. Filed March 22, 2012; issued September 27,
2012.
|
